BioXcel Therapeutics (BTAI) PT Raised to $52 at UBS
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Price: $0.83 +3.75%
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UBS analyst Colin Bristow raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $52.00 (from $23.00) while maintaining a Buy rating.
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Moderna (MRNA) PT Raised to $77 at JPMorgan
- Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
